Amgen has introduced IMDELLTRA™ (tarlatamab-dlle), the first and only T-cell engager therapy for treating extensive-stage small cell lung cancer (ES-SCLC).
IMDELLTRA™ is unique as the only DLL3-targeting bispecific T-cell engager therapy that activates the patient's own T cells to attack DLL3-expressing tumour cells. IMDELLTRA™ (tarlatamab-dlle) is specifically indicated for adult patients with ES-SCLC who have experienced disease progression following platinum-based chemotherapy.
It has received accelerated approval based on promising response rates and duration of response (DoR) observed in clinical studies. IMDELLTRA™ provides much-needed hope to patients urgently in need of innovative therapies, this long-awaited effective treatment.
Lung cancer remains a complex and devastating disease, with less than 3 percent of ES-SCLC patients surviving beyond five years.
After decades of stagnation in the treatment options for small cell lung cancer (SCLC), a breakthrough has emerged in the form of IMDELLTRA™, a targeted bispecific therapy. This innovative treatment marks a pivotal moment for the SCLC community, offering renewed hope and possibilities for those battling this aggressive disease.
With IMDELLTRA™, patients now have access to a treatment that addresses the specific mechanisms driving SCLC progression, potentially leading to improved outcomes and quality of life. This advancement represents a significant milestone in the fight against SCLC and underscores the power of innovation in transforming cancer care.
